KR20260037664A - 게놈을 조절하기 위한 방법 및 조성물 - Google Patents
게놈을 조절하기 위한 방법 및 조성물Info
- Publication number
- KR20260037664A KR20260037664A KR1020247011680A KR20247011680A KR20260037664A KR 20260037664 A KR20260037664 A KR 20260037664A KR 1020247011680 A KR1020247011680 A KR 1020247011680A KR 20247011680 A KR20247011680 A KR 20247011680A KR 20260037664 A KR20260037664 A KR 20260037664A
- Authority
- KR
- South Korea
- Prior art keywords
- domain
- sequence
- genetically modified
- cas
- modified polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241953P | 2021-09-08 | 2021-09-08 | |
| US63/241,953 | 2021-09-08 | ||
| US202263373444P | 2022-08-24 | 2022-08-24 | |
| US63/373,444 | 2022-08-24 | ||
| PCT/US2022/076045 WO2023039424A2 (en) | 2021-09-08 | 2022-09-07 | Methods and compositions for modulating a genome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20260037664A true KR20260037664A (ko) | 2026-03-18 |
Family
ID=85507644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247011680A Pending KR20260037664A (ko) | 2021-09-08 | 2022-09-07 | 게놈을 조절하기 위한 방법 및 조성물 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US12024728B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4399292A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024533311A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20260037664A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022343268A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3231677A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311225A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024002927A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202323522A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023039424A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019327449B2 (en) | 2018-08-28 | 2026-04-09 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| IL296095A (en) | 2020-03-04 | 2022-11-01 | Flagship Pioneering Innovations Vi Llc | Improved methods and compositions for genome modulation |
| BR112022017715A2 (pt) | 2020-03-04 | 2022-11-16 | Flagship Pioneering Innovations Vi Llc | Métodos e composições para modular um genoma |
| EP4095246A1 (en) * | 2021-05-27 | 2022-11-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel crispr grnas |
| CA3231712A1 (en) | 2021-09-08 | 2023-03-16 | Flagship Pioneering Innovations Vi, Llc | Pah-modulating compositions and methods |
| KR20260037664A (ko) | 2021-09-08 | 2026-03-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 게놈을 조절하기 위한 방법 및 조성물 |
| IL312965A (en) * | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and their uses |
| EP4444362A4 (en) | 2021-12-10 | 2026-04-01 | Flagship Pioneering Innovations Vi Llc | CFTR COMPOSITIONS AND MODULATION METHODS |
| JP2026525612A (ja) | 2023-07-25 | 2026-07-31 | フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー | Casエンドヌクレアーゼ及び関連方法 |
| KR20260044217A (ko) | 2023-07-25 | 2026-04-01 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | Cas 엔도뉴클레아제 및 관련 방법 |
| WO2025072331A1 (en) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| IL327927A (en) * | 2023-10-22 | 2026-06-01 | Tessera Therapeutics Inc | Lipid nanoparticles for delivery of therapeutic payloads to t cells |
| WO2025117877A2 (en) | 2023-12-01 | 2025-06-05 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025194138A1 (en) * | 2024-03-14 | 2025-09-18 | Tessera Therapeutics, Inc. | St1cas9 compositions and methods for modulating a genome |
| WO2026015832A2 (en) * | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Reverse transcriptases and gene editing systems comprising such |
| WO2026135182A1 (ko) * | 2024-12-19 | 2026-06-25 | 주식회사 씨젠 | 돌연변이 m-mlv 역전사 효소 |
Family Cites Families (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| CA2196419C (en) | 1994-08-20 | 2007-08-21 | Yen Choo | Improvements in or relating to binding proteins for recognition of dna |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US6699663B1 (en) | 1995-12-14 | 2004-03-02 | The General Hospital Corporation | Molecular sequence of swine retrovirus |
| US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6503717B2 (en) | 1999-12-06 | 2003-01-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
| EP1083231A1 (en) | 1999-09-09 | 2001-03-14 | Introgene B.V. | Smooth muscle cell promoter and uses thereof |
| AU2001250774B2 (en) | 2000-02-08 | 2005-01-27 | Sangamo Biosciences, Inc. | Cells expressing zinc finger proteins for drug discovery |
| AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| US6627424B1 (en) | 2000-05-26 | 2003-09-30 | Mj Bioworks, Inc. | Nucleic acid modifying enzymes |
| US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| US7169874B2 (en) | 2001-11-02 | 2007-01-30 | Bausch & Lomb Incorporated | High refractive index polymeric siloxysilane compositions |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| US7375234B2 (en) | 2002-05-30 | 2008-05-20 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| EP1636343B1 (en) | 2003-05-28 | 2013-08-21 | The Johns-Hopkins University | Synthetic mammalian retrotransposon gene |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| KR100437889B1 (ko) * | 2003-08-26 | 2004-07-07 | 주식회사 인트론바이오테크놀로지 | 세망내피증 바이러스의 역전사 효소 및 이를 생산하는 방법 |
| US7070941B2 (en) | 2003-11-17 | 2006-07-04 | Board Of Regents, The University Of Texas System | Methods and compositions for tagging via azido substrates |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7253273B2 (en) | 2004-04-08 | 2007-08-07 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
| ATE418346T1 (de) | 2004-04-08 | 2009-01-15 | Sangamo Biosciences Inc | Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen |
| ES2547381T3 (es) | 2004-04-09 | 2015-10-05 | Monsanto Technology, Llc | Composiciones y procedimientos de control de infestaciones de insectos en plantas |
| EP2397490B1 (en) | 2004-07-16 | 2013-09-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV |
| DE102004034461B4 (de) | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| ES2716864T3 (es) | 2007-06-06 | 2019-06-17 | Monsanto Technology Llc | Genes y usos para la mejora de plantas |
| JP2011512326A (ja) | 2007-12-31 | 2011-04-21 | ナノコア セラピューティクス,インコーポレイテッド | 心不全の治療用のrna干渉 |
| US8394604B2 (en) | 2008-04-30 | 2013-03-12 | Paul Xiang-Qin Liu | Protein splicing using short terminal split inteins |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| EP2937418B1 (en) | 2008-10-20 | 2017-10-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
| GB0901593D0 (en) | 2009-01-30 | 2009-03-11 | Touchlight Genetics Ltd | Production of closed linear DNA |
| JP5882064B2 (ja) | 2009-03-04 | 2016-03-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 安定化された逆転写酵素融合タンパク質 |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| AU2010325563B2 (en) | 2009-11-27 | 2017-02-02 | Basf Plant Science Company Gmbh | Chimeric endonucleases and uses thereof |
| EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| US8846883B2 (en) | 2011-08-16 | 2014-09-30 | University Of Southhampton | Oligonucleotide ligation |
| PT2877490T (pt) | 2012-06-27 | 2019-02-12 | Univ Princeton | Inteínas clivadas, conjugados e suas utilizações |
| CN102723640B (zh) | 2012-07-09 | 2015-08-26 | 东莞中探探针有限公司 | 磁性连接器结构 |
| CN105209621B (zh) * | 2012-12-12 | 2021-05-25 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| ES2887254T3 (es) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| ES2749624T3 (es) | 2013-03-14 | 2020-03-23 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
| US10378026B2 (en) * | 2013-09-02 | 2019-08-13 | Cellectis | RNA based method to obtain stably integrated retroviral vectors |
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US9663770B2 (en) | 2014-01-22 | 2017-05-30 | Life Technologies Corporation | Reverse transcriptases for use in high temperature nucleic acid synthesis |
| CN113930455A (zh) | 2014-10-09 | 2022-01-14 | 生命技术公司 | Crispr寡核苷酸和基因剪辑 |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| WO2017132580A2 (en) | 2016-01-29 | 2017-08-03 | The Trustees Of Princeton University | Split inteins with exceptional splicing activity |
| EP3417062B1 (en) | 2016-02-15 | 2024-06-26 | Temple University - Of The Commonwealth System of Higher Education | Excision of retroviral nucleic acid sequences |
| ES3030658T3 (en) | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| US11427838B2 (en) | 2016-06-29 | 2022-08-30 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders |
| WO2018045321A1 (en) | 2016-09-02 | 2018-03-08 | North Carolina State University | Methods and compositions for modification of plastid genomes |
| WO2018049075A1 (en) | 2016-09-07 | 2018-03-15 | Flagship Pioneering, Inc. | Methods and compositions for modulating gene expression |
| US11280790B2 (en) | 2016-10-04 | 2022-03-22 | Svar Life Science Ab | System and products for improved quantification of ADCC activity |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| US20190330620A1 (en) | 2016-10-14 | 2019-10-31 | Emendobio Inc. | Rna compositions for genome editing |
| US20180127759A1 (en) | 2016-10-28 | 2018-05-10 | Massachusetts Institute Of Technology | Dynamic genome engineering |
| WO2018089860A1 (en) | 2016-11-11 | 2018-05-17 | 2D Genomics Inc. | Methods for processing nucleic acid samples |
| US9816093B1 (en) | 2016-12-06 | 2017-11-14 | Caribou Biosciences, Inc. | Engineered nucleic acid-targeting nucleic acids |
| EP3551757A1 (en) | 2016-12-08 | 2019-10-16 | Intellia Therapeutics, Inc. | Modified guide rnas |
| EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| WO2019005955A1 (en) | 2017-06-27 | 2019-01-03 | Yale University | ENHANCED REVERSE TRANSCRIPTASE AND METHODS OF USE THEREOF |
| WO2019040650A1 (en) | 2017-08-23 | 2019-02-28 | The General Hospital Corporation | GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY |
| CN111315889A (zh) | 2017-09-08 | 2020-06-19 | 生命技术公司 | 提高同源重组的方法和其组合物 |
| EP3688162B1 (en) | 2017-09-29 | 2024-03-06 | Intellia Therapeutics, Inc. | Formulations |
| IL311278B2 (en) | 2017-09-29 | 2026-05-01 | Intellia Therapeutics Inc | Polynucleotides, compositions, and methods for genome editing |
| WO2019070843A1 (en) | 2017-10-03 | 2019-04-11 | Board Of Regents, The University Of Texas System | INVERSE TRANSCRIPTASE WITH LTR-FREE BACKLIGHTS AND USES THEREOF |
| JP2021505159A (ja) | 2017-12-06 | 2021-02-18 | ジェネレーション バイオ カンパニー | 修飾型閉端dna(cedna)を使用する遺伝子編集 |
| CA3084825A1 (en) | 2017-12-14 | 2019-06-20 | Crispr Therapeutics Ag | Novel rna-programmable endonuclease systems and their use in genome editing and other applications |
| US11293019B2 (en) | 2017-12-22 | 2022-04-05 | Gflas Life Sciences, Inc. | Chimeric genome engineering molecules and methods |
| CA3092459A1 (en) | 2018-03-02 | 2019-09-06 | Generation Bio Co. | Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes |
| DK3765616T3 (da) | 2018-03-14 | 2023-08-21 | Arbor Biotechnologies Inc | Nye enzymer og systemer målrettet crispr dna og rna |
| US11339385B2 (en) | 2018-03-25 | 2022-05-24 | GeneTether, Inc. | Modified nucleic acid editing systems for tethering donor DNA |
| CA3104989A1 (en) | 2018-03-27 | 2019-10-03 | G+Flas Life Sciences | Sequence-specific in vivo cell targeting |
| CA3105953A1 (en) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| WO2020033083A1 (en) | 2018-08-10 | 2020-02-13 | Cornell University | Optimized base editors enable efficient editing in cells, organoids and mice |
| AU2019327449B2 (en) | 2018-08-28 | 2026-04-09 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| WO2020068897A1 (en) | 2018-09-25 | 2020-04-02 | Massachusetts Institute Of Technology | Engineered dcas9 with reduced toxicity and its use in genetic circuits |
| CA3121191A1 (en) | 2018-11-28 | 2020-06-04 | Crispr Therapeutics Ag | Optimized mrna encoding cas9 for use in lnps |
| JP7646552B2 (ja) | 2019-01-31 | 2025-03-17 | ビーム セラピューティクス インク. | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| SG11202108812SA (en) * | 2019-02-15 | 2021-09-29 | Sigma Aldrich Co Llc | Crispr/cas fusion proteins and systems |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020241869A1 (ja) * | 2019-05-30 | 2020-12-03 | 国立大学法人東京大学 | 2種の核酸塩基変換酵素が融合されたCasタンパク質を利用したゲノム編集システム |
| US20220298495A1 (en) | 2019-06-12 | 2022-09-22 | Emendobio Inc. | Novel genome editing tool |
| CA3147875A1 (en) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Recombinase compositions and methods of use |
| WO2021042047A1 (en) | 2019-08-30 | 2021-03-04 | The General Hospital Corporation | C-to-g transversion dna base editors |
| EP4034659A4 (en) | 2019-09-27 | 2024-10-16 | The Broad Institute, Inc. | PROGRAMMABLE POLYNUCLEOTIDE EDITORS FOR AMPLIFIED HOMOLOGOUS RECOMBINATION |
| WO2021080922A1 (en) * | 2019-10-21 | 2021-04-29 | The Trustees Of Columbia University In The City Of New York | Methods of performing rna templated genome editing |
| JP7785002B2 (ja) * | 2019-11-05 | 2025-12-12 | ペアーワイズ プランツ サービシズ, インコーポレイテッド | 対立遺伝子のrnaにコードされたdnaの置換のための組成物および方法 |
| EP4061940A4 (en) | 2019-11-22 | 2024-10-23 | Flagship Pioneering Innovations VI, LLC | RECOMBINASE COMPOSITIONS AND METHODS OF USE |
| US20230051661A1 (en) | 2019-12-26 | 2023-02-16 | Agency For Science, Technology And Research | Nucleobase Editors |
| WO2021138469A1 (en) * | 2019-12-30 | 2021-07-08 | The Broad Institute, Inc. | Genome editing using reverse transcriptase enabled and fully active crispr complexes |
| BR112022017715A2 (pt) | 2020-03-04 | 2022-11-16 | Flagship Pioneering Innovations Vi Llc | Métodos e composições para modular um genoma |
| AU2021232005A1 (en) | 2020-03-04 | 2022-09-29 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| IL296095A (en) | 2020-03-04 | 2022-11-01 | Flagship Pioneering Innovations Vi Llc | Improved methods and compositions for genome modulation |
| US20230348939A1 (en) | 2020-03-04 | 2023-11-02 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| BR112022017735A2 (pt) | 2020-03-05 | 2022-11-29 | Flagship Pioneering Innovations Vi Llc | Métodos e composições de supressão de defesa de hospedeiro para modular um genoma |
| WO2021188840A1 (en) | 2020-03-19 | 2021-09-23 | Rewrite Therapeutics, Inc. | Methods and compositions for directed genome editing |
| CN115427566A (zh) | 2020-04-08 | 2022-12-02 | 阿斯利康(瑞典)有限公司 | 用于改善的位点特异性修饰的组合物和方法 |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| WO2021248102A1 (en) | 2020-06-05 | 2021-12-09 | Flagship Pioneering Innovations Vi, Llc | Template guide rna molecules |
| AU2021403660A1 (en) | 2020-12-16 | 2023-07-06 | Universitat Pompeu Fabra | Programmable transposases and uses thereof |
| AU2022206476A1 (en) | 2021-01-11 | 2023-07-20 | President And Fellows Of Harvard College | Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision |
| CN116745428A (zh) | 2021-01-14 | 2023-09-12 | 加利福尼亚大学董事会 | 位点特异性基因修饰 |
| WO2022155532A1 (en) | 2021-01-15 | 2022-07-21 | 4M Genomics Inc. | Polypeptide fusions or conjugates for gene editing |
| KR102876548B1 (ko) | 2021-01-21 | 2025-10-30 | 한국생명공학연구원 | Francisella novicida Cas9 모듈 기반의 역전사 효소를 사용한 유전체 치환 및 삽입 기술 |
| US20230374476A1 (en) | 2021-02-05 | 2023-11-23 | University Of Massachusetts | Prime editor system for in vivo genome editing |
| US20240132916A1 (en) | 2021-02-09 | 2024-04-25 | The Broad Institute, Inc. | Nuclease-guided non-ltr retrotransposons and uses thereof |
| WO2022183210A1 (en) | 2021-02-26 | 2022-09-01 | Flagship Pioneering Innovations Vi, Llc | Tissue-specific methods and compositions for modulating a genome |
| EP4314257A4 (en) | 2021-04-01 | 2025-07-09 | Prime Medicine Inc | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES |
| EP4352230A4 (en) | 2021-06-03 | 2025-06-11 | Prime Medicine, Inc. | Genome editing compositions and methods for treating Wilson's disease |
| WO2023283092A1 (en) | 2021-07-06 | 2023-01-12 | Prime Medicine, Inc. | Compositions and methods for efficient genome editing |
| WO2023004439A2 (en) | 2021-07-23 | 2023-01-26 | Prime Medicine, Inc. | Genome editing compositions and methods for treatment of chronic granulomatous disease |
| WO2023015318A2 (en) | 2021-08-05 | 2023-02-09 | Prime Medicine, Inc. | Genome editing compositions and methods for treatment of cystic fibrosis |
| US20240360476A1 (en) | 2021-08-05 | 2024-10-31 | Prime Medicine, Inc. | Genome Editing Compositions and Methods for Treatment of Myotonic Dystrophy |
| AU2022325166A1 (en) | 2021-08-06 | 2024-02-08 | President And Fellows Of Harvard College | Improved prime editors and methods of use |
| WO2023039447A2 (en) | 2021-09-08 | 2023-03-16 | Flagship Pioneering Innovations Vi, Llc | Serpina-modulating compositions and methods |
| CA3231712A1 (en) | 2021-09-08 | 2023-03-16 | Flagship Pioneering Innovations Vi, Llc | Pah-modulating compositions and methods |
| KR20260037664A (ko) | 2021-09-08 | 2026-03-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 게놈을 조절하기 위한 방법 및 조성물 |
| WO2023039586A1 (en) | 2021-09-10 | 2023-03-16 | Agilent Technologies, Inc. | Guide rnas with chemical modification for prime editing |
| US20240425831A1 (en) | 2021-10-08 | 2024-12-26 | The General Hospital Corporation | Improved crispr prime editors |
| CA3235826A1 (en) | 2021-10-21 | 2023-04-27 | Wei Hsi Yeh | Genome editing compositions and methods for treatment of usher syndrome type 3 |
| US20250011766A1 (en) | 2021-11-09 | 2025-01-09 | Prime Medicine, Inc. | Genome Editing Compositions and Methods for Treatment of Amyotrophic Lateral Sclerosis |
| US20250319202A1 (en) | 2021-11-09 | 2025-10-16 | Prime Medicine, Inc. | Genome editing compositions and methods for treatment of fuchs endothelial corneal dystrophy |
| EP4430189A1 (en) | 2021-11-11 | 2024-09-18 | Prime Medicine, Inc. | Genome editing compositions and methods for treatment of fragile x syndrome |
| US20250297248A1 (en) | 2021-11-24 | 2025-09-25 | Prime Medicine, Inc. | Methods and compositions for inhibiting mismatch repair |
| AU2022398241A1 (en) | 2021-11-24 | 2024-06-06 | Prime Medicine, Inc. | Modified prime editing guide rnas |
| EP4444362A4 (en) | 2021-12-10 | 2026-04-01 | Flagship Pioneering Innovations Vi Llc | CFTR COMPOSITIONS AND MODULATION METHODS |
| WO2023192655A2 (en) | 2022-04-01 | 2023-10-05 | Prime Medicine, Inc. | Methods and compositions for editing nucleotide sequences |
| CA3260587A1 (en) * | 2022-06-24 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | FAH COMPOSITIONS AND MODULATION METHODS |
-
2022
- 2022-09-07 KR KR1020247011680A patent/KR20260037664A/ko active Pending
- 2022-09-07 EP EP22868275.3A patent/EP4399292A4/en active Pending
- 2022-09-07 WO PCT/US2022/076045 patent/WO2023039424A2/en not_active Ceased
- 2022-09-07 AU AU2022343268A patent/AU2022343268A1/en active Pending
- 2022-09-07 CA CA3231677A patent/CA3231677A1/en active Pending
- 2022-09-07 MX MX2024002927A patent/MX2024002927A/es unknown
- 2022-09-07 JP JP2024515067A patent/JP2024533311A/ja active Pending
- 2022-09-07 IL IL311225A patent/IL311225A/en unknown
- 2022-09-08 TW TW111134204A patent/TW202323522A/zh unknown
-
2023
- 2023-07-20 US US18/356,013 patent/US12024728B2/en active Active
- 2023-08-10 US US18/447,681 patent/US12123034B2/en active Active
- 2023-08-10 US US18/447,536 patent/US12031162B2/en active Active
- 2023-08-10 US US18/447,515 patent/US12037617B2/en active Active
-
2024
- 2024-03-05 US US18/595,904 patent/US20240247243A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240002822A1 (en) | 2024-01-04 |
| EP4399292A2 (en) | 2024-07-17 |
| US20240026324A1 (en) | 2024-01-25 |
| IL311225A (en) | 2024-05-01 |
| US20240076638A1 (en) | 2024-03-07 |
| TW202323522A (zh) | 2023-06-16 |
| CA3231677A1 (en) | 2023-03-16 |
| MX2024002927A (es) | 2024-05-29 |
| EP4399292A4 (en) | 2025-11-12 |
| US20240247243A1 (en) | 2024-07-25 |
| US12037617B2 (en) | 2024-07-16 |
| US12123034B2 (en) | 2024-10-22 |
| JP2024533311A (ja) | 2024-09-12 |
| AU2022343268A1 (en) | 2024-03-28 |
| WO2023039424A2 (en) | 2023-03-16 |
| US12031162B2 (en) | 2024-07-09 |
| US12024728B2 (en) | 2024-07-02 |
| WO2023039424A3 (en) | 2023-07-06 |
| US20240002886A1 (en) | 2024-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12024728B2 (en) | Methods and compositions for modulating a genome | |
| JP2024533313A (ja) | Hbbを調節する組成物及び方法 | |
| US12270029B2 (en) | CFTR-modulating compositions and methods | |
| JP2024533312A (ja) | Serpina調節組成物及び方法 | |
| KR20240099164A (ko) | Pah-조절 조성물 및 방법 | |
| WO2023250492A2 (en) | Fah-modulating compositions and methods | |
| US20260132425A1 (en) | Improved gene editing systems utilizing trans recruiting components | |
| US20250305002A1 (en) | Recruitment in trans of gene editing system components | |
| KR20250158062A (ko) | Serpina-조절 조성물 및 방법 | |
| KR20250158061A (ko) | Pah-조절 시스템 및 방법 | |
| WO2025235506A2 (en) | Atp7b-modulating compositions and methods | |
| WO2023225471A2 (en) | Helitron compositions and methods | |
| CN118489007A (zh) | 调节基因组的方法和组合物 | |
| WO2025194124A1 (en) | Modified st1cas9 guide nucleic acids | |
| EP4646479A2 (en) | Trac and b2m modulating compositions and methods | |
| CN118556123A (zh) | Hbb调节性组合物和方法 | |
| CN118613588A (zh) | Serpina调节组合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |